

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Pfizer Inc.		09/22/2006	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Neurocrine Biosciences, Inc.		
<b>Street Address:</b>	12790 El Camino Real		
<b>City:</b>	San Diego		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	92130		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	78262013	CRESENCE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(212)573-2273		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	212-733-0223		
<b>Email:</b>	cindy.dubiel@pfizer.com		
<b>Correspondent Name:</b>	Christopher N. Bolinger		
<b>Address Line 1:</b>	235 East 42nd Street		
<b>Address Line 4:</b>	New York, NEW YORK 10017		
<b>NAME OF SUBMITTER:</b>	Christopher N. Bolinger		
<b>Signature:</b>	/cnb/		
<b>Date:</b>	09/25/2006		
<b>Total Attachments: 1</b> source=cressenceass#page1.tif			

CH \$40.00 78262013

ASSIGNMENT

WHEREAS, Pfizer Inc. ("Pfizer"), a Delaware corporation, with its principal place of business at 235 E. 42<sup>nd</sup> Street, New York, NY 10017, has intended to use the following mark in commerce and has filed a U.S. trademark application for same indicating that intention, but has not yet filed an allegation of use under §§ 1(c) or 1(d) of The Lanham Act:

Mark	U.S. Trademark Serial No.
CRESENCE	78/262,013

WHEREAS, Pfizer is assigning the mark in the above-identified application as part of the entire business or portion thereof to which the mark pertains as required by 15 U.S.C. § 1060;

WHEREAS, Neurocrine Biosciences, Inc. ("Neurocrine"), a Delaware corporation with its principal place of business at 12790 El Camino Real, San Diego, CA 92130, the successor of the ongoing and existing business of Pfizer to which the mark pertains, is desirous of acquiring said trademark and the pending intent-to-use application therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Pfizer does hereby assign to Neurocrine all right, title and interest in and to the above-referenced trademark and the goodwill of the business symbolized thereby.

Executed: September 22, 2006

Pfizer Inc.

By *Tiffany Trunko*  
Tiffany Trunko  
Senior Corporate Counsel—Trademarks

Subscribed to and sworn before me  
this 22<sup>nd</sup> day of September, 2006  
in the County of New York, State of New York

*Rosalba Oliveri*

**ROSALBA OLIVERI**  
Notary Public, State of New York  
No. 01OL6085628  
Qualified in Queens County  
Certificate Filed in New York County  
Commission Expires December 30, 2006

